Brucker Corporation (NASDAQ: BRKR) recently appointed Laura Francis as an independent director to its board. She is expected to join Brucker's audit committee as a financial expert after the company's annual shareholder meeting in May 2025. Francis, currently the CEO and a board member of Si-Bone, Inc. (NASDAQ: SIBN), previously served as the CFO and COO of the same company. Before her time at Si-Bone, she held executive and leadership roles at public and private life science companies, including Brucker Corporation. Furthermore, she has experience at McKinsey & Company and Coopers & Lybrand.
Francis was also a board member of Shockwave Medical, Inc. (NASDAQ: SWAV), where she served as the audit committee chair and compensation committee member. She holds a B.B.A. in accounting and finance from the University of Wisconsin and an M.B.A. from Stanford University and is a certified public accountant (inactive) in the state of California.
Frank H. Laukien, Chairman, President, and CEO of Brucker Corporation, expressed his warm welcome to Francis, emphasizing her experience as a public company medtech CEO, CFO, and COO in both the medtech and life science tools industries.
Brucker Corporation, a leader in the post-genomic era, offers high-performance scientific instruments and analytical and diagnostic solutions that enable breakthrough post-genomic discoveries and the development of new applications. The company's focus includes life science molecular and cell biology research, applied and biopharma applications, microscopy and nanoanalysis, industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Brucker's offerings also extend to preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, and clinical microbiology and molecular diagnostics. Today the company's shares have moved -1.3% to a price of $52.21. For more information, read the company's full 8-K submission here.
